News Caplin Point Laboratories Limited NSE India S.E.

Stocks

CAPLIPOINT

INE475E01026

Pharmaceuticals

Market Closed - NSE India S.E. 07:05:07 2026-08-28 EDT			5-day change	1st Jan Change
2,517.20 ^INR	-0.92%		-1.70%	+36.95%

08-14	Caplin Point Laboratories Limited, Q1 2027 Earnings Call, Aug 12, 2026
08-12	Caplin Point Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI

All News

Mentions Relevance

08-14	Caplin Point Laboratories Limited, Q1 2027 Earnings Call, Aug 12, 2026
08-12	Caplin Point Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
08-12	Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2026, Payable on or Before October 24, 2026	CI
05-14	Caplin Point Laboratories Limited, Q4 2026 Earnings Call, May 14, 2026
05-14	Caplin Point Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
05-14	Caplin Steriles Limited Gets Usfda Approval for Foscarnet Sodium Injection	CI
05-14	Caplin Point Laboratories' Consolidated Profit Rises in Fiscal Q4; Shares Jump 10%	MT
05-14	Caplin Point Laboratories March-quarter consol net profit 1.7 bln rupees	RE
05-05	Caplin Point Laboratories Unit Gets US FDA's Final Nod for Calcium Gluconate Injection	MT
03-13	Caplin Point Laboratories Unit Gets US FDA's Nod for Potassium Phosphates Injection	MT
03-13	Caplin Point Laboratories unit receives final USFDA approval for ANDA potassium phosphates injection	RE
03-03	Caplin Point Laboratories Limited Announces Cessation of C K Gariyali as Independent Director, with Effect from the Close of Business Hours on March 03, 2026	CI
02-24	Caplin Point Laboratories Arm Gets US FDA's Final Approval for Sodium Phosphates Injection	MT
02-24	Caplin Point Laboratories says unit receives USFDA approval for sodium phosphates injection	RE
02-05	Caplin Point Laboratories Limited, Q3 2026 Earnings Call, Feb 05, 2026
02-05	Caplin Point Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
02-05	Caplin Point Laboratories Dec-quarter consol net profit 1.64 billion rupees	RE
02-03	Caplin Point Laboratories Limited Announces Changes to Its Board	CI
01-27	Caplin Point Laboratories unit receives USFDA approval for methylprednisolone acetate	RE
12-09	Caplin Point Laboratories Gets US FDA Nod for Linezolid Injection	MT
12-09	Caplin Point Laboratories unit gets USFDA final approval for Linezolid Injection, Infusion bags	RE
12-08	Caplin Point Laboratories unit receives final US FDA approval for its ANDA Acetaminophen Injection	RE
11-06	Caplin Point Laboratories Limited, Q2 2026 Earnings Call, Nov 06, 2025
11-05	Caplin Point Laboratories appoints Ashok Partheeban as vice-chairman	RE
11-05	Caplin Point Laboratories Limited Announces Executive Changes , Effective November 5, 2025	CI